- Home
- NVRO vs VYGR Comparison
NVRO vs VYGR Comparison
Compare NVRO & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRO
- VYGR
- Stock Information
- Founded
- NVRO 2006
- VYGR 2013
- Country
- NVRO United States
- VYGR United States
- Employees
- NVRO N/A
- VYGR N/A
- Industry
- NVRO Medical/Dental Instruments
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- NVRO Health Care
- VYGR Health Care
- Exchange
- NVRO Nasdaq
- VYGR Nasdaq
- Market Cap
- NVRO 214.2M
- VYGR 235.4M
- IPO Year
- NVRO 2014
- VYGR 2015
- Fundamental
- Price
- NVRO $5.73
- VYGR $4.22
- Analyst Decision
- NVRO Hold
- VYGR Strong Buy
- Analyst Count
- NVRO 12
- VYGR 9
- Target Price
- NVRO $7.24
- VYGR $15.53
- AVG Volume (30 Days)
- NVRO 1.7M
- VYGR 380.0K
- Earning Date
- NVRO 02-28-2025
- VYGR 03-03-2025
- Dividend Yield
- NVRO N/A
- VYGR N/A
- EPS Growth
- NVRO N/A
- VYGR N/A
- EPS
- NVRO N/A
- VYGR 0.47
- Revenue
- NVRO $419,146,000.00
- VYGR $163,784,000.00
- Revenue This Year
- NVRO N/A
- VYGR N/A
- Revenue Next Year
- NVRO $0.23
- VYGR N/A
- P/E Ratio
- NVRO N/A
- VYGR $9.05
- Revenue Growth
- NVRO N/A
- VYGR 3.40
- 52 Week Low
- NVRO $3.17
- VYGR $4.00
- 52 Week High
- NVRO $16.12
- VYGR $10.66
- Technical
- Relative Strength Index (RSI)
- NVRO 70.16
- VYGR 29.98
- Support Level
- NVRO $4.77
- VYGR $4.20
- Resistance Level
- NVRO $5.80
- VYGR $4.60
- Average True Range (ATR)
- NVRO 0.13
- VYGR 0.31
- MACD
- NVRO -0.01
- VYGR -0.08
- Stochastic Oscillator
- NVRO 93.20
- VYGR 12.36
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.